Results 251 to 260 of about 222,467 (377)

Assessing Battery-Related Challenges in Insulin Pump Therapy: Insights From a Brazilian Diabetes Center. [PDF]

J Diabetes Sci Technol
Neves ALD, Martins LEG, Gabbay MAL, Arêdes SV, Tenorio FS, Rabello Casali K, Cunha TS.   +6 more
europepmc   +1 more source

Metabolic control and hypoglycaemia in people with type 1 diabetes: insulin pump therapy vs. intensified insulin therapy in an unselected cohort in routine care. [PDF]

Diabetol Metab Syndr, 2021
Kramer G, Kloos C, Müller UA, Wolf G, Kuniss N.   +4 more
europepmc   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Characteristics of people with type 1 diabetes influence the educational process for starting insulin pump therapy: an observational study. [PDF]

Health Educ Res
Izquierdo V, Pazos-Couselo M, González-Rodríguez M, Martínez-Santos AE, Andujar-Plata P, Díaz-Trastoy O, Fernández-Pombo A, Sigüeiro-Paulos S, Rodríguez-González R.   +8 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Retraction: Insulin Pump Therapy vs Multiple Daily Insulin Injections for Glycemic Control in Children With Type 1 Diabetes: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Calderon Martinez E, Castillo JL, Zachariah Saji S, Stein D, Khan TJ, Guardado Williams RF, Munguía ID, Arruarana VS, Velasquez K.   +8 more
europepmc   +1 more source

Influence af acute iodine incorporation on thyroid function and thyroidal iodine content [PDF]

, 1981
Habermann, J., Leisner, B., Pickardt, C. R., Scriba, Peter Christian, Witte, A.   +4 more
core   +1 more source

Clinical pharmacology and prescribing education: An updated medical school curriculum from the British Pharmacological Society

British Journal of Clinical Pharmacology, EarlyView.
Aims Prescribing is a complex, essential skill that doctors must acquire to practice medicine safely and effectively. The British Pharmacological Society has historically provided a core curriculum to guide clinical pharmacology and prescribing education in UK medical schools.
Dagan O. Lonsdale, Clare Guilding, Jennifer Koenig, Michael Okorie, Reecha Sofat, Simon Maxwell   +5 more
wiley   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, EarlyView.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source